Marea Therapeutics Presents Positive Data from Phase 2a Clinical Trial of MAR001, Being Developed for Cardiovascular Disease, in Late-Breaking Oral Session at the 93
'We are very excited by these data from our Phase 2a study, which demonstrate the strong potential of MAR001 to address the most important unaddressed lipid and metabolic drivers of atherosclerotic cardiovascular disease in high-risk patients,' said Josh Lehrer, M.D., M.Phil., FACC, chief executive officer of Marea. 'We look forward to advancing MAR001 into Phase 2b development for treating residual cardiovascular risk in patients who remain at highest risk despite aggressive standard of care therapies.'
'Atherosclerotic cardiovascular disease patients with elevated remnant cholesterol remain at an increased risk for major adverse cardiovascular events despite best available standard of care therapies,' said Ethan Weiss, M.D., chief scientific officer of Marea. 'These data clearly validate the ability of MAR001 to significantly lower remnant cholesterol and triglycerides by inhibiting ANGPTL4, supporting genetic findings and expected translation to substantial cardiovascular disease risk reduction. We believe MAR001 has the potential to become an important new therapeutic option for patients.'
Presentation Highlights:
The primary objective of Marea's randomized, double-blind, placebo-controlled Phase 2a clinical trial was to characterize the safety and tolerability of multiple doses of MAR001 in participants with elevated triglycerides and remnant cholesterol.
Secondary objectives were to describe the serum concentration of MAR001 at selected timepoints and to characterize the effect of MAR001 on triglyceride and remnant cholesterol metabolism following 12 weeks of treatment.
The study enrolled 55 participants with hypertriglyceridemia (fasting TGs ≥151 and ≤496 mg/dL) randomized to Q2W MAR001 or placebo (blinded, 2:1 MAR001:Placebo). Ten participants were randomized to the 150 mg MAR001 arm, nine to the 300 mg MAR001 arm, 17 to the 450 mg MAR001 arm, and 19 to placebo.
MAR001 demonstrated up to a 52.5% placebo-adjusted mean reduction in remnant cholesterol and up to a 52.7% placebo-adjusted mean reduction in triglycerides at 12 weeks.
In participants with significantly elevated triglyceride levels at baseline (≥200 mg/dL), MAR001 demonstrated up to a 66.0% placebo-adjusted mean reduction in remnant cholesterol and up to a 64.0% placebo-adjusted mean reduction in triglycerides at Week 12.
MAR001 was generally well tolerated, with no clinically significant findings, and no findings of elevated systemic inflammatory biomarkers or changes in mesenteric lymph node (MLN) size or local inflammation as assessed by MRI. There were no deaths or serious adverse events in any arm, and no adverse events with MAR001 leading to study drug discontinuation.
Table 1: Mean Placebo-Adjusted Reductions in Remnant Cholesterol and Triglyceride (TG) at 12 Weeks
Presentation Details:
Title: A Novel ANGPTL4 Inhibitory Antibody Safely Lowers Plasma Triglycerides and Remnant Cholesterol in Humans
Abstract Number: 1320
Session Title: Late Breaker Session: Clinical
Session Date and Time: Wednesday, May 7, 2025, 11:00 a.m. – 12:30 p.m. BST
Title: Real-world Analysis of the Association of Remnant Cholesterol Levels with Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease
Abstract Number: 1314
Session Title: SaaG Session: Epidemiology: From Prevention to Prognosis
Session Date and Time: Tuesday, May 6, 2025, 2:35 p.m. – 3:35 p.m. BST
About Remnant Cholesterol
Remnant cholesterol is carried by triglyceride-rich lipoproteins, is highly atherogenic, and drives cardiovascular events independent of classical risk factors like LDL cholesterol, diabetes or obesity. There are currently no available targeted therapies to lower remnant cholesterol and improve metabolic function.
About MAR001
MAR001 is a first-in-class monoclonal antibody that targets ANGPTL4, a protein that is highly expressed in adipose tissue. By inhibiting ANGPTL4 and thereby augmenting lipoprotein lipase (LPL) activity, MAR001 is designed to lower remnant cholesterol and improve adipose tissue function. Human genetic data has identified ANGPTL4 as a highly promising therapeutic target because loss of function alleles leads to lower remnant cholesterol, improved adipose distribution, improved insulin sensitivity, lower triglyceride levels, and protection from cardiovascular disease and type 2 diabetes.
MAR001 is being developed to reduce the risk of major adverse cardiovascular events (MACE) in adults with established atherosclerotic cardiovascular disease (ASCVD) plus elevated triglycerides and remnant cholesterol.
Preclinical models with MAR001 demonstrated reduction in triglycerides, remnant cholesterol and ectopic fat, and improved insulin sensitivity. Results from a Phase 2a study of MAR001 demonstrated clinically meaningful reductions in remnant cholesterol and triglycerides. Marea plans to advance MAR001 into Phase 2b clinical development in the second quarter of 2025.
About Marea Therapeutics
Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases. The company's lead therapy, MAR001, is in Phase 2 clinical development for adults with metabolic dysfunction and high risk for cardiovascular disease. The company is also advancing MAR002 for the treatment of acromegaly. To learn more, please visit www.mareatx.com and follow us on LinkedIn and X.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Epoch Times
11 hours ago
- Epoch Times
Malfunctioning Insulin Pumps Recalled After 59 Injuries
San Diego-based Tandem Diabetes Care, Inc. is voluntarily recalling insulin pumps used to manage blood sugar, the company said in an Aug. 12 announcement by the Food and Drug Administration. Insulin pumps are wearable devices that deliver insulin at predetermined doses at specific times. Such devices can feature alarm functions to alert users about various situations, such as issues with insulin delivery.
The Hill
13 hours ago
- The Hill
Obamacare faces a subsidy cliff — don't bail it out without reform
The controversy over the 2010 Affordable Care Act dominated Barack Obama's presidency. The implementation of ObamaCare caused health insurance premiums to soar and nearly collapsed the market entirely. The Biden administration responded by flooding the system with expanded federal subsidies, which are set to expire at the end of 2025. To stop premiums for older workers with pre-existing conditions from suddenly leaping by $10,000, Republicans will need to extend part of this additional funding. But in return, they should insist on reforms to allow healthy Americans to purchase better value insurance with their own money. The Affordable Care Act required health insurers to cover individuals with pre-existing conditions at the same price as enrollees who signed up before they got sick. As a result, premiums more than doubled, millions of healthy enrollees dropped coverage and many insurers abandoned the market. The Affordable Care Act kept the individual health insurance market from falling apart completely by providing subsidies to low-income enrollees. But individuals earning more than $62,600 in 2025 would have faced full premiums without any assistance. Those unsubsidized enrollees felt the full pain of the Affordable Care Act's premium hikes. The legislation allows insurers to charge older enrollees up to three times what they do the youngest, and so unsubsidized premiums for near-retirees can be huge. This year, the benchmark unsubsidized premium for a 61-year-old individual in Washington, D.C., is $15,402 per year. Rather than fix ObamaCare's structure, the newly-elected Democratic Congress in 2021 threw money at the problem with the American Rescue Plan Act. By expanding eligibility for subsidies to higher earners, the act reduced the cost of health insurance for a 61-year-old earning $70,000 from $15,402 to $5,950 — with federal taxpayers covering the difference. That legislation also expanded the generosity of subsidies for lower earners. Those earning $22,000, who would have contributed $756 to the cost of insurance under the original Affordable Care Act, would get it entirely paid for by the federal government. This approach has been hugely expensive. In May 2022, the Congressional Budget Office estimated that subsidies for the Affordable Care Act would cost $67 billion in 2024. Last June, following a renewal of the American Rescue Plan Act's increased subsidies, the Congressional Budget Office's revised cost estimate for 2024 surged to $129 billion. A recent Paragon Institute report found that this leap in cost owed much to a surge in enrollment among those who received coverage free of charge. Paragon estimated that such enrollees accounted for nearly half of new enrollment, and that 5 million people may have misreported their income to claim free coverage, costing taxpayers an additional $20 billion. Insurers eagerly welcomed the influx of new healthy enrollees, who had not deemed it worth purchasing insurance from the individual market until the federal government paid the entire price. Such newcomers proved enormously lucrative, as they used less medical care than existing enrollees but generated the same revenue. Democrats, who received twice as much in campaign contributions as Republicans from Blue Cross Blue Shield in 2024, eagerly boasted about reducing the number of uninsured Americans, with little concern for the cost. The expiry of the American Rescue Plan Act subsidies is now looming again, set to expire at the end of 2025. It will be up to a Republican president and Republican-led Congress to find a way forward. Fiscal conservatives have little appetite to pay for renewing all the expanded ObamaCare subsidies. But nor will they feel comfortable letting the American Rescue Plan Act's enhanced subsidies expire entirely, as this would result in a $10,000-per-year premium hike on thousands of middle-income near-retirees. Congress should focus on targeted support by eliminating the cap on eligibility for the Affordable Care Act's original subsidies, which limit premiums at 9.5 percent of income, to avoid a sudden benefit cliff for those with incomes just above $62,600. But they should also let other expansions of subsidies expire. In return, Republicans should insist that Americans be allowed to obtain discounted premiums if they purchase insurance before they get sick. In 2017, President Trump allowed Americans to do this by purchasing short-term insurance. However, in 2024, the Biden administration limited the duration of these plans to four months. This came following pressure from big insurers, who claimed that allowing the expansion of such plans would prevent them from cross-subsidizing enrollees with pre-existing conditions by overcharging those who signed up while healthy. In reality, the restriction of these affordable plans has served mostly to inflate insurers' profits. Healthy enrollees remain able to purchase short-term plans afresh every few months; it is only those who subsequently become sick who are deprived of coverage. Regulatory protections for the long-term coverage of enrollees in non-ObamaCare plans should be strengthened; not weakened. Furthermore, with the extension of the American Rescue Plan Act's premium cap, federal subsidies taxpayers directly subsidize most enrollees. It is therefore unnecessary to also prohibit healthy enrollees from obtaining insurance plans which offer long-term coverage at good value for their money.
Time Business News
a day ago
- Time Business News
Next-Gen Bioremediation Technologies Revolutionize Environmental Cleanup
Bioremediation is the process of using living organisms, such as germs, fungi, or plants, to make the environment clean and safe, to break or neutralize pollutants from soil, water and air. The bioremediation market is increasing due to increasing environmental concerns, strict government rules on pollution control, increasing industrial waste and demand for environmentally friendly and cost -effective cleaning methods. Increased awareness about progress and sustainable practices in biotechnology is moving forward in areas such as oil and gas, agriculture and waste water treatment. Key Growth Drivers and Opportunities Increasing Environmental Concerns: Increasing environmental concerns are driving the growth of the bioremediation market as governments, industries, and communities seek sustainable and eco-friendly solutions to combat pollution. With increasing awareness about industrial waste, oil spread, and contaminated soil and harmful effects of water, the demand for natural and less aggressive cleaning methods is increasing. Bioremediation provides an effective, cost-efficient and environmentally safe option for traditional therapeutic techniques, causing widespread adoption and market expansion in areas. Challenges The bioremediation market faces limitations such as microbial or slow speed of plant-based cleanup processes, which may not be suitable for emergency or large-scale contamination. Effectiveness may be unexpectedly due to the presence of toxins that disrupt microbial activity such as temperature, pH, and toxins. Additionally, bioremediation is often limited to specific types of pollutants and may require a wider site monitoring. Using genetically modified organisms (GMOs) can cause regulatory approval and widely adopting public skepticism. Innovation and Expansion The New Glyphosate Bioremediation Solution Revealed by Ancient Organics In May 2023, PaleoPower will go on sale, according to Ancient Organics Bioscience, Inc., an agricultural technology firm that creates its own line of plant and soil probiotics. The only substance that is known to decompose glyphosate contamination in soil naturally is PaleoPower. A group of helpful microbes called PaleoPower breaks down glyphosate. The active component of Roundup and other popular glyphosate-based herbicides is glyphosate. PaleoPower decreased soil glyphosate levels by more than 80% during 90 days of treatment and by more than 90% within 180 days of application in controlled tests. An Innovative Approach to Address Acid Mine Drainage in Northeast Coal Mines IIT Guwahati Develops In June 2022, The Indian Institute of Technology Guwahati A study on the 'bioremediation' of Acid Mine Drainage (AMD) in Constructed Wetlands has been conducted by researchers using coal mines. This is the first research to show how constructed wetlands may be used to bioremediate AMD from the Northeastern Coalfields (NEC). The term 'acid mine drainage' describes the acidic wastewater produced by coal mines (or any polymetallic mine) that contains significant levels of iron, sulfate, and other hazardous heavy metals. This study addresses the long-term operational sustainability concerns that arise in constructed wetlands that receive AMD while offering an effective sustainable treatment method to reduce AMD contamination. To further comprehend the operation of several basic processes that co-occur in constructed wetlands, a biochemical mechanism has been established. Inventive Sparks, Expanding Markets Major development strategies for bioremediation companies include investing in advanced microbial and genetic technologies, expanding applications in industries such as agriculture, oil and gas and waste water, forming partnership with environmental agencies and focusing on permanent, low -cost solutions. Companies aim to increase operations through government cooperations and regulatory approval by increasing R&D for targeted and rapid therapeutic methods. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
